Key result
Administration of rsPSGL.Ig significantly reduced myocardial necrosis compared to a mutant form (16% vs. 42% of area-at-risk, P<0.01) in a feline model of ischemia-reperfusion injury.
Why the study?
Does recombinant soluble P-selectin glycoprotein ligand-1 reduce myocardial necrosis in cats subjected to myocardial ischemia-reperfusion injury?
Does recombinant soluble P-selectin glycoprotein ligand-1 reduce myocardial necrosis in cats subjected to myocardial ischemia-reperfusion injury?
Absolute Event Rate: 16% vs 42%
p-value: p=<0.01
Recombinant soluble PSGL-1 reduces myocardial reperfusion injury and preserves vascular endothelial function in a feline model by reducing neutrophil-endothelial cell interactions.
No takes yet. Share an insight, caveat, or question.
May inform neutrophil-targeted cardioprotection strategies; leaves open translation from feline models to clinical use.
Reid Hayward (1999) studied Myocardial ischemic reperfusion injury. Recombinant soluble human form of P-selectin glycoprotein ligand-1 (rsPSGL.Ig) vs. Low affinity mutant form of rsPSGL.Ig (1 mg/kg) was evaluated on Myocardial necrosis (% of area-at-risk) (p=<0.01). Administration of rsPSGL.Ig significantly reduced myocardial necrosis compared to a mutant form (16% vs. 42% of area-at-risk, P<0.01) in a feline model of ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: